NGD-4715
-4-((3,4-dimethoxyphenyl)methyl)piperazine.png) | |
| Identifiers | |
|---|---|
| |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H24BrN3O3 |
| Molar mass | 422.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
NGD-4715 is a drug developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal studies it has anxiolytic, antidepressant and anorectic effects,[1] and it has successfully passed Phase I clinical trials in humans.[2]
Neurogen was acquired by Ligand Pharmaceuticals in August, 2009, and NGD-4715 was not listed among the key assets in the Business Wire article.[3] All four laboratories were closed and sold, and no employees were retained.[4] Neurogen's domain name is delisted. No reference to NGD-4715, nor MCH Antagonists exists on ligand.com as of 2011-09-04. Internet searches as of 2011-09-04 for Phase-II come up negative.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
References
- ^ Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. Drugs of the Future. 2007;32(9):809.
- ^ Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity. Business Wire. May 2 2007
- ^ Neurogen acquired by Ligand Pharmaceuticals. Business Wire. August 24, 2009.
- ^ Neurogen to sell Real Estate for $3.5m. Chicago Tribune. Nov 10, 2009